STAT+: Unraveling of Amicus spinout spells more trouble for gene therapy field
The abrupt dissolution of a blank-check merger on Thursday points to more trouble for the already deflated gene therapy field.
Amicus Therapeutics called off a planned spinout of its gene therapy division via a combination with a special purpose acquisition company, or SPAC. The $600 million deal, announced five months ago, would have created a new publicly traded gene therapy company called Claritas Therapeutics.
